Trastuzumab-MCC-DM1 (Tmab-MCC-DM1), a first-in-class HER2 antibody-drug conjugate (ADC) - A phase I study in patients (pts) with HER2+ metastatic breast cancer (BC) Meeting Abstract
| Authors: | Beeram, M.; Krop, I. E.; Modi, S.; Tolcher, A. W.; Tibbitts, J.; Rabbees, N.; Girish, S.; Lutzker, S. G.; Holden, S. N.; Burris, H. A. |
| Abstract Title: | Trastuzumab-MCC-DM1 (Tmab-MCC-DM1), a first-in-class HER2 antibody-drug conjugate (ADC) - A phase I study in patients (pts) with HER2+ metastatic breast cancer (BC) |
| Meeting Title: | 5th International Symposium on Targeted Anticancer Therapies |
| Journal Title: | Annals of Oncology |
| Volume: | 18 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2007 Mar 8-10 |
| Meeting Location: | Amsterdam, The Netherlands |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2007-06-01 |
| Start Page: | iv21 |
| Language: | English |
| ACCESSION: | WOS:000249280500016 |
| PROVIDER: | wos |
| PUBMED: | 17915341 |
| DOI: | 10.1093/annonc/mdm153 |
| Notes: | Meeting Abstract: O.403 - 5th International Symposium onTargeted Anticancer Therapies - MAR 08-10, 2007 - Amsterdam, NETHERLANDS - "Source: Wos" |
